Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Vascular Diseases Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Vascular Diseases. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Vascular Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2: 1.

Research is led by Pulnovo Medical (Wuxi) Co., Ltd. (1), VahatiCor, Inc. (1), Insel Gruppe AG, University Hospital Bern (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Pulmonary arterial denervation (procedure, 1 trial), followed by Guideline-directed medical therapy (GDMT) for heart failure, A-FLUX Reducer System.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track Vascular Diseases trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 3NCT05824923

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension...

It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF)...

Sponsor: Pulnovo Medical (Wuxi) Co., Ltd.Enrolling: 2641 location
RECRUITINGNCT07449325

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates...

Sponsor: VahatiCor, Inc.Enrolling: 302 locations
RECRUITINGNCT06954610

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism...

Sponsor: Insel Gruppe AG, University Hospital BernEnrolling: 5001 location
RECRUITINGNCT06297291

Global Paradise System US Post Approval Study

The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for...

Sponsor: ReCor Medical, Inc.Enrolling: 100020 locations
RECRUITINGPhase 2NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated...

Sponsor: Pulmovant, Inc.Enrolling: 201 location
RECRUITINGNCT06067789

The ALOFT Pilot Trial

The ALOFT Pilot Trial will evaluate three pragmatic elements (recruitment, adherence, and follow-up) of neuraxial versus general anesthesia for lower limb revascularization...

Sponsor: Ottawa Hospital Research InstituteEnrolling: 901 location
RECRUITINGNCT05134311

Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies

The ability to have a visual aid to depict areas of vascular disease that are affecting the patient's health can help in patient comprehension of the problem. This comprehension...

Sponsor: Northwell HealthEnrolling: 2701 location
RECRUITINGNCT07427108

Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety

The study aims to compare the technical feasibility and safety of road mapping-guided versus ultrasound-guided retrograde arterial puncture in patients with (CLTI) as measured by:...

Sponsor: Sohag UniversityEnrolling: 321 location
RECRUITINGNCT05309707

ENDOBARC-S Study: "Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain"

The ENDOBARC-S post-market clinical follow-up study is undertaken to evaluate the prevention of death related to aortic arch pathologies when treated by branch stent graft systems...

Sponsor: Vascular Investigation Network Spanish Society for Angiology and Vascular SurgeryEnrolling: 1001 location
RECRUITINGNCT06603363

Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT

INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for...

Sponsor: Prof. Maurovich-Horvat PálEnrolling: 1401 location

Frequently Asked Questions

There are currently 10 clinical trials for Vascular Diseases, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Vascular Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Vascular Diseases, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.